Overexpression of GRIM-19 accelerates radiation-induced osteosarcoma cells apoptosis by p53 stabilization

This study was designed to investigate the role and the underlying mechanism of GRIM-19 in osteosarcoma progression.Materials and methodsOsteosarcoma tissues and cell lines were utilized to analyze the expressions of GRIM-19 in osteosarcoma by qRT-PCR and Western blot. Methods containing flow cytometry, irradiation exposure, cells inoculation, plasmid transfection, and protein immunoprecipitation were used to investigate the underlying mechanisms of GRIM-19 in osteosarcoma progression.Key findingsGRIM-19 is downregulated in osteosarcoma tissues and cell lines. Exposure to radiation induces osteosarcoma cell apoptosis by upregulation of p53 both in U2OS (p53-wt) and exogenous p53-introduced MG-63 (p53-null) osteosarcoma cells. Overexpression of GRIM-19 accelerates radiation-induced osteosarcoma cells apoptosis by p53 stabilization ex vivo and in vivo. Mechanistically, forced expression of GRIM-19 diminishes the activity of E3 ubiquitin-protein ligase mouse double minute 2 homolog (MDM2), a specific p53 protease, results in the accumulation of p53 and activation of p53-mediated apoptosis.SignificanceGRIM-19 was proved to modulate radiation-induced osteosarcoma cells apoptosis in a p53 dependent manner by mediating MDM2 activity, which sheds light on the development of GRIM-19-based molecular target therapy on osteosarcoma.
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

Pediatric Blood&Cancer, EarlyView.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: In addition to pretreatment lymphocyte count, LMR during chemotherapy had prognostic significance in pediatric osteosarcoma patients. Further studies involving larger cohorts are necessary to validate our findings. PMID: 30304898 [PubMed - as supplied by publisher]
Source: Korean Journal of Pediatrics - Category: Pediatrics Tags: Korean J Pediatr Source Type: research
ConclusionsThe study provides the first evidence, that BORM treatment is effective against RMA cells with low side effects on healthy cells.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: November 2018Source: Journal of Bone Oncology, Volume 13Author(s): Kehan Song, Jian Song, Feiyan Chen, Kaiyuan Lin, Xiaosheng Ma, Jianyuan JiangAbstractAimThe present study aimed to develop nomograms estimating survival for patients with high-grade osteosarcoma.Methods1990 patients with high-grade osteosarcoma between 1994 and 2013 were retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Data from 12 cancer registries (n = 1460) were used to conduct multivariate Cox analysis to identify independent prognostic factors. Nomograms which estimate 3- and 5-year o...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
(Tufts University) Two studies into deadly cancers in dogs are now underway, offered through the newly formed Clinical Trials Office at Cummings Veterinary Medical Center at Tufts University. Dogs with spontaneous osteosarcoma, as well as dogs with mast cell tumors and solid tumors, may be eligible for enrollment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion: The results of our study are promising, and further studies will be necessary to confirm the applicability of eBAT as a supplementary therapy for a variety of sarcomas, carcinomas, and possibly other refractory malignancies that express EGFR and uPAR. PMID: 30288129 [PubMed]
Source: Clinical Pharmacology: Advances and Applications - Category: Allergy & Immunology Tags: Clin Pharmacol Source Type: research
Authors: Gao F, Xu F Abstract OBJECTIVE: MiR-564 has been reported to be involved in the development of several types of cancers. However, its clinical significance in osteosarcoma (OS) has not been investigated. We aimed to explore the prognostic value of miR-564 in OS patients. PATIENTS AND METHODS: Quantitative RT-PCR assay was used to detect the expression levels of miR-564 in OS tissues and matched normal bone tissues. The correlation between miR-564 expression and clinicopathological features was analyzed by Pearson's χ2-test. The disease-free survival and overall survival rates of OS patients were ca...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: November 2018Source: Pharmacological Research, Volume 137Author(s): Francesca Punzo, Chiara Tortora, Daniela Di Pinto, Elvira Pota, Maura Argenziano, Alessandra Di Paola, Fiorina Casale, Francesca RossiAbstractOsteosarcoma is the most common primary malignant tumor of bone in children and adolescents.Bortezomib (BTZ) is an approved anticancer drug, classified as a selective reversible inhibitor of the ubiquitin-dependent proteasome system, that leads to cancer cell cycle arrest and apoptosis reducing the invasion ability of Osteosarcoma cells in vitro. It also regulates the RANK/RANKL/OPG system, involved...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
MicroRNA‑944 targets vascular endothelial growth factor to inhibit cell proliferation and invasion in osteosarcoma. Mol Med Rep. 2018 Oct 01;: Authors: Yan T, Zhu S, Zhang J, Lu G, Lv C, Wei Y, Luo M Abstract Emerging evidence has demonstrated that the dysregulation of microRNA (miRNA/miR) serves a crucial role in the tumorigenesis and tumor development of osteosarcoma (OS), primarily by affecting various pathological behaviors. Therefore, better knowledge of miRNA in OS may provide novel insights into the pathogenesis of OS, and may facilitate the development of promising therapeutics for patients w...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Biology | Bone Cancers | Cancer | Cancer & Oncology | Genetics | Osteosarcoma | Study